



February 13, 2026

Company Name: GNI Group Ltd.  
Representative: Director, Representative Executive Officer,  
President and CEO  
Ying Luo, PhD  
(Security Code: 2160, TSE Growth)  
Contact Person: Director, Executive Officer, Vice President  
COO and CFO  
Ryosuke Matsui  
(TEL. 03-6214-3600)

**Notice Regarding the Postponement of the Disclosure of FY2026 Consolidated  
Earnings Forecast and Earnings Briefing**

(Note) This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.

The Company announced today its financial results for the fiscal year ended December 31, 2025. However, the Company has decided to postpone the disclosure of the “Full-Year Consolidated Earnings Forecast for the Fiscal Year Ending December 31, 2026” and the “Earnings Presentation Materials,” which have typically been released concurrently.

Accordingly, the earnings briefing that had been scheduled for Tuesday, February 24, 2026, will also be postponed.

**1. Reasons for the Postponement**

**(1) Ensuring Fair Disclosure in Relation to U.S.-Listed Subsidiary Gyre Therapeutics, Inc.**

Gyre Therapeutics, Inc. (“Gyre Therapeutics”), a consolidated subsidiary of the Company, is scheduled to announce its financial results in mid-March 2026. The segment-level detailed information and business outlook for fiscal year 2026 included in the Company’s earnings presentation materials are closely linked to the performance of Gyre Therapeutics. Disclosure or explanation of such information by the Company prior to Gyre Therapeutics’ official announcement could raise concerns under U.S. securities regulations, including potential violations of Fair Disclosure rules. Therefore, the Company has determined that it is appropriate to disclose such information after Gyre Therapeutics has made its official announcement.

**(2) Difficulty in Reasonably Estimating the Full-Year Consolidated Earnings Forecast**

The consolidated earnings forecast for the fiscal year ending December 31, 2026, is expected to be significantly affected by factors such as the approval and launch timing, as well as the assumed drug pricing, of F351, a treatment for liver fibrosis caused by chronic hepatitis B for which Gyre Therapeutics is

currently preparing a New Drug Application (NDA), and the research and development progress of Cullgen, Inc. At this stage, it is difficult to reasonably estimate these factors. Accordingly, the Company has decided to temporarily refrain from disclosing its earnings forecast and to classify it as “undetermined.”

## 2. Background of Management’s Decision

The primary reason for revising the disclosure policy from this fiscal year is that F351, the most critical project at Gyre Therapeutics, is entering a pivotal phase toward NDA submission in the first half of 2026.

F351 has the potential to become a first-in-class therapy, and strict information management in accordance with global standards is essential to ensure the success of this project. The Company has concluded that thorough compliance with such standards will ultimately contribute to the maximization of shareholder value.

## 3. Outlook

### (1) Disclosure of Earnings Presentation Materials

Following the completion of Gyre Therapeutics’ earnings announcement scheduled for mid-March 2026, the Company will announce the disclosure schedule.

### (2) Full-Year Consolidated Earnings Forecast

The Company will promptly disclose the earnings forecast once a reasonable estimation becomes possible.

The Company appreciates stakeholders’ understanding as it continues to strengthen its global governance framework.